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Hepatocarcinogenesis is tightly linked to liver fibrosis. Recently, two GWAS variants, MICA rs2596542 
and DEPDC5 rs1012068 were identified as being associated with the development of HCV-induced 
hepatocellular carcinoma (HCC) in Japanese patients. The role of these variants on hepatic inflammation 
and fibrosis that are closely associated with HCC development is not known, nor are the biological 
mechanisms underlying their impact on the liver. Here, we demonstrate in 1689 patients with chronic 
hepatitis C (CHC) (1,501 with CHC and 188 with HCV-related HCC), that the MICA (t) allele, despite not 
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being associated with HCC susceptibility, is associated with increased fibrosis stage (OR: 1.47, 95% 
CI: 1.05–2.06, p = 0.02) and fibrosis progression rate (hazards ratio: 1.41, 95% CI: 1.04–1.90, p = 0.02). 
the DEPDC5 variant was not associated with any of these phenotypes. MICA expression was down-
regulated in advanced fibrosis stages. Further, (T) allele carriage was associated with lower MICA 
expression in liver and serum. transforming growth factor-β1 (TGF-β1) expression suppresses MICA 
expression in hepatic stellate cells. Our findings suggest a novel mechanism linking susceptibility to 
advanced fibrosis and subsequently indirectly to HCC, to the level of MICA expression through TGF-β1-
dependent mechanisms.
Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma (HCC) and 
liver transplantation, with an estimated 339,000 people dying annually from complications1. Advanced liver fibro-
sis or cirrhosis represents the major risk factor for developing liver-related complications and mortality, but cur-
rently there are no approved anti-fibrotic therapies2.
The rate of liver fibrosis progression varies greatly according to disease etiology and also between individuals; 
the latter is at least partially attributable to genetic factors. In chronic HCV infection, host genetics play a pivotal 
role in shaping the immune response, virus-host interactions and ultimately the predilection to and progress of 
liver fibrosis3,4. This risk is likely polygenic and dependent on multiple genetic and epigenetic factors since vari-
ations in single loci are usually of modest effect size and explain only a small fraction of the phenotype5. This has 
led in the recent past to a shift towards the discovery of novel variants with limited effects which ultimately could 
guide the development of polygenic scores with high predictive value.
Two genome wide association studies (GWAS) have investigated the risk of HCV-related HCC in Japanese 
patients. The first identified a locus in the 5′ flanking region of the MHC class I-related chain A (MICA) on 
6p21.33 (rs2596542) to be strongly associated with HCC and the progression from CHC to HCC6. MICA is a 
ligand for natural-killer group 2 member D (NKG2D), a highly conserved C-type lectin-like membrane glyco-
protein and one of the major activating receptors on NK cells7. The second GWAS identified a susceptibility locus 
near DEPDC5 (rs1012068)8. The function of DEPDC5 is not well understood, but has been linked with hereditary 
forms of epilepsy9, bladder cancer10 and malignant glioblastomas11.
Complicating the interpretation of these findings however is that HCC development in chronic HCV infection 
is tightly linked to hepatic fibrosis with 90% of cases arising in cirrhotic livers12. Hence, risk variants that predis-
pose to fibrosis could be associated with HCC formation without direct causality and disentangling the two is 
problematic. In this regard, little is known about the potential effect of variants in MICA and DEPDC5 on liver 
fibrosis since both GWAS were done in patients in whom liver biopsy was not available. Importantly, functional 
data on the role of these variants with regard to both fibrosis pathways or HCC development are limited. The 
available literature is also restricted to Japanese populations with chronic HCV infection and HCC, while a single 
report in Caucasians13 suggests that DEPDC5 but not MICA is associated with fibrosis progression.
Here we sought to dissect the role of MICA rs2596542 and DEPDC5 rs1012068 to liver fibrosis and to 
HCV-related HCC. To do this, these variants were assessed in 1,501 patients with CHC of Caucasian ancestry 
in whom liver biopsy was available and were compared to 188 patients with CHC-related HCC. We undertook 
functional studies to explore the mechanisms that might underlie the genetic association with fibrosis.
Results
patient characteristics. The clinical, demographic and biochemical characteristic of the patients in the 
cohort with chronic HCV infection (n = 1501) are presented in Supplementary Table 1. The genotype distri-
bution of MICA rs2596542 and DEPDC5 rs1012068 was in Hardy-Weinberg equilibrium and is presented in 
Supplementary Table 2. The minor allele frequency (MAF) for the two variants was similar to that observed in a 
healthy European population from the 1000 genome project (http://browser.1000genomes.org), which has some 
difference from the Japanese population.
Association of MICA rs2596542 and DEPDC5 rs1012068 with viral and clinical character-
istics. To explore if baseline clinical variables differ between chronic HCV patients according to MICA 
rs2596542 or DEPDC5 rs1012068 genotype, we examined the association of the genotypes with baseline clinical 
variables; the results are presented in Supplementary Tables 3 and 4, respectively. There was no evidence of asso-
ciation between either rs2596542 or rs1012068 genotype with any clinical variable (i.e. age, BMI, baseline levels 
of ALT, AST, GGT, ALP, platelets, leukocytes, HCV-RNA quantification, gender frequency or HCV genotype 
distribution).
MICA rs2596542, but not DEPDC5 rs1012068 is associated with fibrosis severity. We next 
assessed the association between MICA rs2596542 and DEPDC5 rs1012068 and liver damage (hepatic inflam-
mation and fibrosis). The distribution of rs2596542 and rs1012068 genotypes according to histological features 
is depicted in Fig. 1.
First, we examined the association of the two genetic variants with fibrosis. In multivariate analyses adopting 
an additive model adjusted for age, gender, BMI, HCV genotype and alcohol intake, MICA rs2596542 was signif-
icantly associated with stage of fibrosis (adjusted estimate, 0.072, SE, 0.051; p = 0.01) (Supplementary Table 5). 
In further analysis when the cohort was segregated into those with mild (F0–1) versus advanced fibrosis (F2–4), 
carriage of each copy of the MICA rs2596542 (T) allele was associated consistently with a significant increased 
risk of advanced fibrosis, independent of age, gender, BMI, HCV genotype and alcohol intake (OR: 1.47, 95% CI: 
1.05–2.06, p = 0.02) (Supplementary Table 6). Similarly, rs2596542 was associated with severe fibrosis (F3-F4) 
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(OR: 1.43, 95% CI: 1.03–1.99, p = 0.03). On the contrary, we did not observe any association between DEPDC5 
rs1012068 and stage of fibrosis (Supplementary Table 5); the distribution of rs1012068 genotypes was also not sig-
nificantly different according to the presence or absence of significant or severe fibrosis (Supplementary Table 6).
We next examined the association of the two genetic variants with hepatic inflammation defined by liver his-
topathology scored according to METAVIR. Neither MICA rs2596542 nor DEPDC5 rs1012068 demonstrated any 
association with inflammation grade (Supplementary Table 5). No association was also observed when the cohort 
was dichotomized into absent/mild (A0–A1) versus moderate/severe (A2–A3) inflammation (Supplementary 
Table 6). Consistently, no difference was noted in serum liver enzymes (ALT or AST; as indices of liver injury) 
according to rs2596542 or rs1012068 (Supplementary Tables 3 and 4, respectively).
Association between MICA rs2596542 and fibrosis progression. To validate these observations, we 
undertook analysis in the 815 patients from the entire cohort with chronic HCV infection and a known duration 
of infection. This allowed assessment of the relationship to fibrosis progression without the inherent biases of 
cross sectional analyses. The baseline characteristics of the cohort were similar among subjects included and 
not included in the fibrosis progression sub-analysis (Supplementary Table 7). As the fibrosis progression rate 
(FPR) may not be constant over time14, we used Cox-proportional hazards analysis. In this analysis, rs2596542 
was associated with an increased hazard of progression to significant fibrosis (≥F2) in a multivariate model that 
included age, gender, BMI and HCV genotype (hazards ratio: 1.41, 95% CI: 1.04–1.90, p = 0.02 per each T allele). 
In contrast, DEPDC5 rs1012068 was not associated with FPR (hazards ratio: 1.06, 95% CI: 0.76–1.48, p = 0.7) 
(Supplementary Table 8). In sum, these data suggest that MICA rs2596542 but not DEPDC5 rs1012068 is associ-
ated with fibrosis severity and fibrosis progression.
Chronic HCV infection increases hepatic MICA expression. In the subsequent studies reported below, 
we sought to define the functional basis for the association of variants in MICA to liver fibrosis. The expression 
of MICA is low in healthy tissues but can be induced by cellular stressors such as viral infection15; the effect of 
HCV infection on hepatic MICA expression is not known. We therefore compared MICA expression in liver 
Figure 1. Association of MICA rs2596542 and DEPDC5 rs1012068 with inflammation, fibrosis stage. 
Association of MICA rs2596542 with fibrosis stage (a) and inflammation (b) and DEPDC5 rs1012068 with 
fibrosis stage (c) and inflammation (d) in the CHC cohort (n = 1501). P-values are univariate and provided for 
the additive model of inheritance. MICA rs2596542 (T) allele is the risk allele, the same risk allele in the GWAS 
by Kumar et al.6. DEPDC5 rs1012068 (G) allele is the risk allele, the same risk allele in the GWAS by Miki et al.8.
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from patients with HCV and from control, non-infected subjects. RT-PCR demonstrated increased MICA mRNA 
expression in patients with chronic HCV infection (Fig. 2a). We then assessed MICA expression in the JFH1/
Huh7 in vitro model of replicating HCV. Consistently, Huh7 cells infected with the JFH1 strain of HCV demon-
strated a 3-fold upregulation of MICA mRNA compared to control uninfected cells (Fig. 2b), p < 0.05).
The biological effect of MICA in HCV-infected liver likely reflects a complex interaction between the different 
cell types within an inflamed liver that ultimately leads to fibrosis. Hence, we examined the expression of MICA 
in four primary human hepatic cell types, namely hepatocytes, Kupffer cells, hepatic sinusoidal endothelial cells 
and stellate cells by real time PCR. The highest expression of MICA was in stellate cells followed by Kupffer cells, 
while sinusoidal cells and hepatocytes had low expression (Supplementary Fig. 1).
Membranous and soluble MICA levels associate with MICA genotype and fibrosis severity. 
Whether the MICA risk allele is associated with altered membrane bound (mMICA) expression in liver tissue 
Figure 2. Hepatic and serum MICA expression. Relative hepatic MICA mRNA expression in 94 patients with 
chronic hepatitis C virus infection and 28 controls (a); relative MICA mRNA expression in Huh7 cells infected 
with the JFH1 strain hepatitis C virus as compared to mock infected control cells (b); correlation between MICA 
rs2596542 genotype and hepatic MICA mRNA (c) and soluble MICA levels (n = 214) (d). The x axis shows the 
genotypes at rs2596542 and the y axis shows MICA expression level relative to GAPDH by quantitative real-
time PCR or the concentration of soluble MICA in pg/ml by ELISA, respectively. The level of hepatic MICA 
mRNA correlates positively with serum soluble MICA levels in a sub-cohort of CHC with available RNA and 
serum (n = 58) (e); hepatic MICA mRNA according to hepatic fibrosis (f). The x axis shows hepatic fibrosis 
dichotomized as absent/mild (METAVIR stage F0–F1) or moderate/severe (METAVIR stage F2–F4), and the y 
axis shows hepatic MICA expression. The number of independent samples tested in each group is shown below 
the figure and P value was calculated using the two-tailed Student’s t-test or ANOVA test with Tukey test for 
correction for multiple comparisons.
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from patients with chronic HCV infection is not known as all available current data are based on the soluble form 
(sMICA) present in serum6,16. As shown in Fig. 2c, we observed a significant association between rs2596542 gen-
otype and MICA mRNA expression; the (T) allele associated with lower hepatic MICA mRNA in the 94 patients 
with available liver tissue (P = 0.01, p = 0.02 after adjustment for age and sex).
We then measured soluble MICA (sMICA) by ELISA in serum samples from a sub-cohort of 214 chronic 
HCV infection patients; their characteristics are summarized in Supplementary Table 9 and matched the overall 
cohort. Similar to mMICA, compared to patients harboring the MICA rs2596542 CC genotype, sMICA levels 
were significantly reduced in those with the risk T allele (Fig. 2d). We determined the correlation of mMICA to 
sMICA in 58 patients in whom paired liver and serum data was available. In this analysis, levels of sMICA associ-
ated with the expression of mMICA (p = 0.0001) (Fig. 2e).
In total, MICA expression is upregulated in HCV infection in an rs2596542 genotype dependent manner with 
individuals carrying rs2596542 (T) expressing lower levels of mMICA and sMICA. This suggests that differences 
in expression levels of mMICA according to genotype are not a consequence of differing shedding rates of MICA.
MICA expression and liver fibrosis. The overall contribution of the MICA/NKG2D pathway to fibrosis 
is unclear. Interestingly and consistent with the genetic data, hepatic MICA expression was significantly lower 
in subjects with significant hepatic fibrosis (F2–F4) compared to those with no or mild hepatic fibrosis (F0/1) 
(n = 94) (Fig. 2f). MICA expression did not correlate with hepatic inflammation, liver enzymes, HCV-RNA levels 
and genotype, age or gender. Similarly, sMICA levels were decreased in patients with significant fibrosis compared 
to those without, though this was not significant (Supplementary Fig. 2).
MICA expression is regulated by TGF-β1 in hepatic stellate cells. We next thought to explore how 
differential expression of hepatic MICA could be linked to fibrosis progression. Hepatic stellate cells (HSC) are 
responsible for the deposition of extracellular matrix that is evident histologically as fibrosis17 and as we have 
shown, also have the highest expression of MICA. Killing of activated HSCs by NK cells to ameliorate liver fibrosis 
is in part by a MICA/NKG2D-dependent manner18. Thus, we investigated the regulation of MICA expression on 
HSCs in a fibrotic context.
Surface expression of MICA has been reported to be down-regulated by TGF-β119, an established growth fac-
tor mediating liver injury and fibrosis12. Hence, we characterized TGF-β1 mediated regulation of MICA expres-
sion on HSCs. We first assessed expression of TGF-β1 mRNA after HCV infection in vitro using qRT-PCR. This 
revealed a significant increase in TGF-β1 in HCV-infected JFH-1/Huh7 cells compared to non-infected cells 
Figure 3. Transforming growth factor beta influences MICA expression. Relative TGF-β1 mRNA expression 
in Huh7 cells infected with the JFH1 strain of the hepatitis C virus compared to mock infected control cells 
(a); relative hepatic TGF-β1 mRNA expression in 94 patients with chronic hepatitis C virus infection and 28 
controls according to fibrosis stage (b); serum concentration of TGF-β1 in pg/ml levels according to hepatic 
fibrosis (n = 214) (c); MICA mRNA expression and protein levels at the hepatic stellate cell surface modulation 
by TGF-β1. MICA mRNA expression was assessed in control, TGF-β1 (2 ng/ml) with or without LY2109761 
(a TGFβR-I/II inhibitor) (100 nM, was added 90 minutes before TGF-β1), or LY2109761 (100 nM) treated cells 
for 24 hours by real-time PCR (d), or 48 hours for flow cytometry (e); the level of soluble MICA was assessed in 
the supernatant of control or TGF-β1 (2 ng/ml) treated LX2 cells for 24 and 48 hours by ELISA (f). Results are 
expressed, as mean ± sem (n = 3) and P value was calculated using the two-tailed Student’s t-test or ANOVA test 
with Tukey test for correction for multiple comparisons. *P < 0.05,**P < 0.001, ***P < 0.0001.
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(Fig. 3a). Consistently, we observed increased TGF-β1 transcription in liver from chronic HCV infected liver 
samples compared to healthy controls (Fig. 3b). Within the chronic HCV infection group, the expression of 
TGF-β1 mRNA was significantly up-regulated with advancing of fibrosis stage (Fig. 3b) and this was consistently 
observed in the sub-cohort with available serum described above (n = 214) (Fig. 3c).
Given these results, we examined for the effect of TGF-β1 on MICA expression on a human HSC-derived 
cell line (LX2). We observed a marked repression of MICA mRNA transcripts in TGF-β1 stimulated LX2 cells 
(Fig. 3d), as well as reduced surface expression of MICA, by flow cytometry (Fig. 3e). For confirmation that this 
effect was mediated through the TGFβR, we used a specific pharmacological inhibitor of TGFβR-I/II (using 
LY2109761) and this as expected, reversed the inhibitory effect of exogenous TGFβ1 on MICA expression (Fig. 3d 
and e). To characterize the role of endogenous HSC-derived TGF-β1 in the regulation of MICA expression, we 
used LX2 cells treated with LY2109761 and demonstrated a significant induction of MICA mRNA transcripts and 
surface expression levels (Fig. 3d and e).
Lastly, previous reports have observed a positive effect of TGF-β1 treatment on the expression of some 
proteases including MMP-9. Since MICA surface expression can be modulated at a post-translational level by 
proteolytic cleavage20, we asked whether shedding of sMICA was enhanced in TGF-β1 stimulated cells, thus con-
tributing to the attenuation of surface expression on these cells. To this end, we measured sMICA in cell culture 
supernatant and showed that the level of sMICA released by TGF-β1 stimulated cells was not different compared 
with control cells suggesting that cleavage of MICA is not mediated by TGF-β1-dependent proteases (Fig. 3f).
MICA polymorphism is not associated with HCC.  As MICA was originally discovered as a risk locus 
for HCC in Japanese patients, we investigated the role of MICA in hepatocarcinogenesis. We compared MICA 
genotype distribution in patients with chronic HCV-HCC (n = 188) to non-HCC from the entire chronic HCV 
infection cohort described above (n = 1,501; Supplementary Table 10). We observed no difference in MICA 
rs2596542 distribution between subjects with HCC and those without. Because HCC mainly occurs in the 
context of cirrhosis, we undertook similar analysis restricting the comparison to those with HCC versus those 
with chronic HCV infection and cirrhosis (n = 210). Again, no difference in MICA rs2596542 distribution was 
observed between subjects with HCC and those with cirrhosis (p = 0.77). Results were not changed after adjust-
ment for age and sex. These findings imply that MICA rs2596542 polymorphism is unlikely to be directly associ-
ated with the occurrence of HCC.
Discussion
Here, we report that a genetic variant in MICA originally identified by GWAS as a risk variant for suscepti-
bility to HCV-associated HCC in Japanese patients6 associates with fibrosis severity and progression, but not 
with HCC. Functionally our data suggest that the association with HCC is plausibly mediated by indirect effects 
through modulation of fibrosis risk. Following the data for effects on fibrosis progression, we show MICA 
genotype-dependent reductions in hepatic MICA gene expression and soluble MICA protein levels. Tying these 
findings to fibrosis, TGF-β1 was increased with advancement of fibrosis and there was a corresponding reduction 
in MICA expression. In vitro, TGF-β1 treatment resulted in MICA transcriptional and surface protein repression 
on HSC cells. These effects we propose leads to an increased likelihood of fibrosis in those with the risk genotype. 
Our findings therefore suggest a molecular explanation for the association of rs2596542 with liver fibrosis (Fig. 4).
Consistent with the present findings in the setting of chronic HCV infection, a recent report suggests that 
MICA polymorphisms (MICA*012:01/02, MICA*017 and MICA*027) are associated with liver fibrosis in schis-
tosomiasis21. It is noteworthy that in the original GWAS report of MICA in HCV-related HCC, Kumar et al., 
did not use HCV-related cirrhosis without HCC as their control cohort, masking any potential confounding by 
fibrosis6. This and the failure to find an association with MICA in a similar Japanese study published 2 months 
later8, as well as the functional data we provide, suggest that the reported association with HCC actually relates 
to liver fibrosis risk.
MICA is a stress inducible protein present at very low levels in healthy tissues, but can be induced by cellular 
stresses such as viral infection15. Consistently, we demonstrated increases in MICA expression during the early 
stages of HCV infection, while it decreases with increasing fibrosis in an rs2596542 genotype dependent man-
ner. Furthermore, the (T) risk allele correlated with lower mMICA in liver. Consistent with other groups6,16, we 
demonstrated decreased expression levels of sMICA in the serum of patients with the (T) rs2596542 allele.
The mechanisms that link MICA genotypes with fibrosis risk have not been previously elucidated. MICA 
is a ligand for the activating NK cell receptor NKG2D and this interaction shapes the anti-fibrotic capacity of 
NK-cells via elimination of activated HSCs18,22 We verified that HCV infection is associated with an increase in 
TGF-β1 expression in liver23 and the latter induces marked repression of MICA expression in HSC. This suggests 
that MICA genotype might be associated with alterations in TGF-β1 (through as yet undefined mechanisms) and 
may underlie the accelerated fibrosis we observed.
We did not observe any association between DEPDC5 rs1012068, the other variant identified by GWAS as a 
risk variant for HCC8, with either fibrosis or HCC. A large Japanese study of 2,266 HCV patients who had erad-
icated HCV and with long term follow up to 20 years, was also unable to find any association between DEPDC5 
SNPs at rs1012068 and the cumulative risk of HCC24. Some studies have reported an association of DEPDC5 
with fibrosis but with opposite effects of the risk allele13,25,26. A recent smaller study conducted in Europeans 
suggested an association between DEPDC5 rs1012068 but not MICA rs2596542 and risk of cirrhosis in chronic 
HCV infection13. The reasons for the discrepancy between our study and this work are unclear, but may relate to 
differences in baseline characteristics and that the association analyses for fibrosis were performed differently, as 
those authors compared F0-F1 vs. F4. Interestingly, in that study, MICA rs2596542 showed a tendency for signifi-
cance with cirrhosis (p = 0.07) in the discovery cohort (n = 477) but was not investigated in the validation cohort. 
The function of DEPDC5 in liver needs to be defined.
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Our study has some limitations, including the fact that the sample size of the PCR and ELISA sub-cohorts 
was relatively modest. In addition, whether MICA rs2596542 is the functional polymorphism or if there are 
other variants in linkage disequilibrium and the detailed functional mechanisms for the effects are still not fully 
understood.
In conclusion, we have demonstrated that MICA rs2596542 is associated with liver fibrosis progression, likely 
mediated and amplified in part through TGFβ-1 dependent mechanisms.
Methods
patient cohort. The study comprised 1689 consecutive patients (1,501 with CHC and 188 with HCV-
related HCC) from the International Liver Disease Genetics Consortium (ILDGC) database. Details of the 
cohort and inclusion criteria have been reported27–29. Briefly, all subjects who had a liver biopsy with scoring 
for fibrosis stage and disease activity before anti-viral treatment, and genomic DNA were included. For those 
with CHC, those with HCV RNA serum positivity of Self-reported Caucasian descent were included. Patients 
were excluded if they had evidence of co-infection with other hepatitis viruses, other liver diseases by stand-
ard tests or current or previous hepatic decompensation. Diagnosis of HCC was based on the EASL–EORTC 
Clinical Practice Guidelines30.
The study protocol was conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Ethics 
approval was obtained from the Human Research Ethics Committees of the Western Sydney Local Health District 
and the University of Sydney. All other sites had ethics approval from their respective ethics committees and study 
was performed according to the recommendations of the centers involved. Written informed consent for genetic 
testing was obtained from all participants.
Clinical and laboratory assessment. The following data were collected at time of liver biopsy from all 
patients: gender, age, ethnicity, recruitment center, alcohol intake (g/day), body mass index (BMI) and routine 
laboratory tests. BMI was calculated as weight divided by the square of the height (kg/m2).
Methods to estimate the duration of infection. Fibrosis progression was examined in 815 chronic 
HCV infection patients with a reliable estimated duration of infection, as previously reported31,32. Briefly, for 
subjects with a history of injecting drug use, the time of infection was estimated using the reported “first year of 
injection”. For patients with a history of blood transfusion, the onset of infection was assumed to be the year of 
transfusion. For patients with a history of occupational exposure, the onset of infection was assumed to be the 
first year of needle stick exposure. The duration of infection was calculated by subtracting the estimated age at 
infection from age at biopsy.
Figure 4. Proposed model for the effect of MICA rs2596542 in modulating liver fibrosis risk. Patients carrying 
the MICA risk genotype have low hepatic and serum MICA expression. TGF-β1 further suppresses MICA 
expression on hepatic stellate cells, leading to increased liver fibrosis.
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Genotyping. Genotyping for MICA rs2596542 and DEPDC5 rs1012068 was contracted to the Australian 
Genome Research Facility (AGRF; QLD, Australia). 1051 samples were genotyped using the Sequenom 
MassARRAY system and iPLEX Gold chemistry while 638 samples were genotyped using the TaqMan SNP gen-
otyping allelic discrimination method (Applied Biosystems, Foster City, CA, USA). All genotyping was blinded 
to clinical variables.
Liver histopathology. Liver histopathology was scored according to METAVIR33. Fibrosis was staged from 
F0 (no fibrosis) to F4 (cirrhosis). Necroinflammation (A) was graded as A0 (absent), A1 (mild), A2 (moderate) or 
A3 (severe). The inter-observer agreement between pathologists was studied previously and was good (κ = 77.5) 
for METAVIR staging using κ statistics34.
other methods. Methods for cell culture, real-time PCR, ELISA and flow Cytometry are described in 
Materials and Methods of the Supporting Information
statistical analysis. Statistical analyses were performed using the statistical software package SPSS for 
Windows, version 21 (SPSS, Chicago, IL). All tests were two-tailed and p values < 0.05 were considered signif-
icant. Details of statistical analyses are described in the Materials and Methods of the Supporting Information.
Data Availability
All data are provided within the main text and Supplementary File.
References
 1. WHO. Hepatitis C. Fact sheet. Updated April 2017, http://www.who.int/mediacentre/factssheets/fs164/en/ (accessed 30 July 2017).
 2. Iredale, J. P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117, 
539–48 (2007).
 3. Romero-Gomez, M., Eslam, M., Ruiz, A. & Maraver, M. Genes and hepatitis C: susceptibility, fibrosis progression and response to 
treatment. Liver Int 31, 443–60 (2011).
 4. Eslam, M. & George, J. Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution. 
Semin Liver Dis 35, 402–20 (2015).
 5. Gibson, G. Rare and common variants: twenty arguments. Nat Rev Genet 13, 135–45 (2011).
 6. Kumar, V. et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat 
Genet 43, 455–8 (2011).
 7. Raulet, D. H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3, 781–90 (2003).
 8. Miki, D. et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus 
carriers. Nat Genet 43, 797–800 (2011).
 9. Ishida, S. et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet 45, 552–5 (2013).
 10. Harada, Y. et al. Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder 
cancer cells. Cancer Res 70, 5829–39 (2010).
 11. Seng, T. J. et al. Complex chromosome 22 rearrangements in astrocytic tumors identified using microsatellite and chromosome 22 
tile path array analysis. Genes Chromosomes & Cancer 43, 181–193 (2005).
 12. Zhang, D. Y. & Friedman, S. L. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 56, 769–75 (2012).
 13. Burza, M. A. et al. DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology 
63, 418–27 (2016).
 14. Poynard, T. et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 34, 730–9 (2001).
 15. Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W. & Jung, H. Regulation of ligands for the NKG2D activating receptor. Annu Rev 
Immunol 31, 413–41 (2013).
 16. Huang, C. F. et al. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma 
Development in Chronic Hepatitis C Patients Post Antiviral Treatment. E Bio Medicine 15, 81–89 (2017).
 17. Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14, 397–411 (2017).
 18. Krizhanovsky, V. et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657–67 (2008).
 19. Friese, M. A. et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune 
response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64, 7596–603 (2004).
 20. Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 
419, 734–8 (2002).
 21. Gong, Z. et al. Association of MICA gene polymorphisms with liver fibrosis in schistosomiasis patients in the Dongting Lake region. 
Brazilian Journal of Medical and Biological Research 45, 222–229 (2012).
 22. Radaeva, S. et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor 
necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130, 435–52 (2006).
 23. Taniguchi, H. et al. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol 72, 52–9 (2004).
 24. Nagaoki, Y. et al. Hepatocellular carcinoma development of hepatitis C virus patients with eradication to interferon therapy: a large 
scale, long-term study of 2266 patients. Hepatology 60, 1162a–1163a (2014).
 25. Motomura, T. et al. Neither MICA Nor DEPDC5 Genetic Polymorphisms Correlate with Hepatocellular Carcinoma Recurrence 
following Hepatectomy. HPB Surg 2012, 185496 (2012).
 26. Al-Anazi, M. R. et al. Variations in DEPDC5 gene and its association with chronic hepatitis C virus infection in Saudi Arabia. BMC 
Infect Dis 14, 632 (2014).
 27. Eslam, M. et al. IFN-lambda 3, not IFN-lambda 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and 
fibrosis. Nature Genetics 49, 795–+ (2017).
 28. Thabet, K. et al. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat 
Commun 7, 12757 (2016).
 29. Eslam, M. et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. 
Hepatology 64, 34–46 (2016).
 30. European Association For The Study Of The, L., European Organisation For, R. & Treatment Of, C. EASL-EORTC clinical practice 
guidelines: management of hepatocellular carcinoma. J Hepatol 56, 908–43 (2012).
 31. Eslam, M. et al. Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 
6, 6422 (2015).
 32. Eslam, M. et al. FibroGENE: A gene-based model for staging liver fibrosis. J Hepatol 64, 390–398 (2016).
www.nature.com/scientificreports/
9Scientific RepoRts |          (2019) 9:1439  | https://doi.org/10.1038/s41598-018-35736-2
 33. Bedossa, P. & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. 
Hepatology 24, 289–93 (1996).
 34. Eslam, M. et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol 61, 
235–41 (2014).
Acknowledgements
We would like to thank all the patients for their participation in this study. M.E., C.L., M.D. and J.G. are supported 
by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health 
and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206, APP1149976) and Project 
grants (APP1107178 and APP1108422). G.D. is supported by an NHMRC Fellowship (1028432). U.S. and J.N. are 
supported by DFG SFB-TR57 and the Hector-Foundation (M63). R.E. and K.T. are supported by a scholarship 
from the Egyptian government. A.B. is supported by an Australian Government Research Training Program 
(RTP) scholarship.
Author Contributions
R.E., A.B., M.M., M.E. and J.G. conceived the research; patient enrolment, clinical phenotype data collation 
and sample acquisition/DNA preparation was performed by R.E., A.B., M.M., M.E., J.G., M.R.-G., A.M., W.L.I., 
T.B., G.J.D., D.S., M.L.A., E.B., M.W., L.M., W.C., S.R., R.S., J.F., U.S., J.N., P.L., R.D., R.G.-D., M.W.D., E.B., C.L., 
O.L. and L.Q. genotyping was performed by K.T., M.M. histological analysis of tissues was conducted by D.M.; 
statistical analysis and interpretation of results was performed by R.E., A.B., M.M., M.E. and J.G.; RT–PCR: R.E.; 
ELISA: A.B.; Tissue culture: R.E., JFH-1 data: M.A.M.N., the manuscript was written and revised by R.E., A.B., 
M.M., M.E. and J.G. All authors critically reviewed the manuscript and approved the final submitted manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-35736-2.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
www.nature.com/scientificreports/
1 0Scientific RepoRts |          (2019) 9:1439  | https://doi.org/10.1038/s41598-018-35736-2
Consortia
International Liver Disease Genetics Consortium (ILDGC)
Rose White1, Angela Rojas4, Margaret Bassendine20, Chiara Rosso5, Lavinia Mezzabotta7, 
Reynold Leung1, Barbara Malik3, Gail Matthews8, Jason Grebely8, Vincenzo Fragomeli12 & 
Julie R. Jonsson8
20institute of translational Medicine, newcastle University, tyne, UK. 
